Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800822 · ClinicalTrials.gov registry record · Phase 1
PF-07284892 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT04800822 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 53 participants.
The verdict
NCT04800822, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.
Interventions
- DRUG binimetinib
- BIOLOGICAL cetuximab
- DRUG encorafenib
- DRUG lorlatinib
- DRUG PF-07284892
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04800822
The ClinicalTrials.gov registry entry for NCT04800822 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which binimetinib is the first listed.
NCT04800822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04800822 about?
NCT04800822 is a clinical study titled "PF-07284892 in Participants With Advanced Solid Tumors". The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and pr...
What is the current status of trial NCT04800822?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2021-03-17. Estimated completion is 2024-06-19.
What interventions are being tested in trial NCT04800822?
The interventions under investigation include: binimetinib (DRUG), cetuximab (BIOLOGICAL), encorafenib (DRUG), lorlatinib (DRUG), PF-07284892 (DRUG).
Who is sponsoring clinical trial NCT04800822?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.